Tumor suppressing pathways in renal cancer
Tumor suppressing pathways in renal cancer
批准号:
10252173
负责人:
Maria F Czyzyk-Krzeska
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
未结题
起止时间:
2011-07-01 至 2025-06-30
关键词:
ATP Synthesis PathwayAffectAgeAge-YearsAmino AcidsAnabolismAspartateAutophagocytosisAutophagosomeBioenergeticsC-terminalCell ProliferationCitric Acid CycleClear cell renal cell carcinomaCleaved cellClinicalComplexCoupledCytoplasmCytosolDataDatabasesDigestionElementsEnzymesEpidemiologyFelis catusGenderGenesGenetic TranscriptionGlucoseGlutamatesGlycolysisHealthHumanHydroxylationIncidenceInvestigational TherapiesIonsLifeLightLipidsMAP1 Microtubule-Associated ProteinMaintenanceMalate-Aspartate Shuttle PathwayMalatesMalignant NeoplasmsMediatingMedicalMembraneMetabolicMetabolismMilitary PersonnelMitochondriaModelingMolecularNADHNatural regenerationOncogenicOutputOxidation-ReductionPathway interactionsPentosephosphate PathwayPentosephosphatesPeptidesPersonsPopulationPrimatesProcessProcollagen-Proline DioxygenaseProlineRegulationRenal Cell CarcinomaRenal carcinomaRiskRisk FactorsRoleStructureTestingTobacco smoking behaviorTumor Suppressor ProteinsVeteransWarburg EffectWorkantiportercancer cellcaveolin 1former smokergene repressionglucose metabolismlysosomal proteinsmalemilitary veterannew therapeutic targetnoveloxidationparalogous genepreventservice memberstemnesstherapeutic targettumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Clear cell renal cell carcinoma (ccRCC) is a serious health concern for military personnel, particularly males beyond
40 years of age, including military veterans. According to The Defense Medical Epidemiology Database for 1995-2004
the incidence of RCC specifically for military members after the 4th decade of life is dramatically increased to 8.5 as
compared to 1.5 cases per 100,000 person-years of the overall incidence. This proposal investigates direct
mechanistic connection between selective autophagy and glucose metabolism in the context of renal cancer
cells. Autophagy is a tightly regulated process of self-digestion. Formation of an autophagosome requires
lipidation and insertion of microtubule associated protein 1 light chains A, B and C (MAP1LC3A, B, C, referred
to as LC3A, LC3B, and LC3C) into the autophagosomal membrane. We established that LC3C autophagy is
tumor suppressing and functions downstream form VHL, tumor suppressor lost in clear cell renal cell carcinoma.
LC3C is an evolutionary late gene, present only in higher primates and humans, that contains a unique and
conserved C-terminal 20 amino acid peptide that is cleaved during initiation of LC3C autophagy. The C-terminal
peptide of LC3C has a proline hydroxylation motif similar to the canonical motifs in HIFαs, where prolines are
hydroxylated by 2-oxyglutarate (2OG)-dependent EGLN proline hydroxylases. Our preliminary data indicate that
P133 within the LC3C peptide undergoes hydroxylation by EGLN3 proline hydroxylase in an autophagy-
dependent manner. Recently we discovered that LC3C autophagy requires glucose metabolic flux. In turn, loss
of LC3C increases the steady-state levels of glycolytic and pentose phosphate metabolites, representing
hallmarks of oncogenic form of metabolism (Warburg effect) particularly relevant in ccRCC. We determined that
LC3C co-immunoprecipitates and targets for autolysosomal degradation malate/2-oxyglutarate(2OG) and
aspartate /glutamate antiporters, SCL25A11 and SLC25A13, respectively that are part of the mitochondrial
malate-aspartate shuttle (MAS). MAS transfers reducing equivalents between mitochondria and cytoplasm,
yielding mitochondrial NADH for ATP synthesis while generating cytosolic NAD to sustain glycolysis. Additionally,
the shuttle exchanges glutamate and aspartate that contributes to biosynthetic potential. We propose a novel,
metabolism-coupled mechanism of tumor suppressing LC3C activity: LC3C autophagy targets MAS proteins for
lysosomal degradation in the process of mitophagy. This acts as a checkpoint for glycolysis by regulating
cytosolic NAD/NADH ratio, as well as for SLC25A13-mediated export of aspartate from mitochondria. That
indicates that LC3C metabolically partners with transcriptional effects of VHL inhibiting glycolysis. Moreover, we
hypothesize that selective activation of LC3C autophagy in the proximity to mitochondrial carriers is caused by
2OG derived from glucose through the TCA cycle and transported through the SLC25A11 which activates
EGLN3, leading to P133 hydroxylation. Here we will mechanistically investigate metabolic inputs and functional
output of LC3C autophagy in regard to MAS in the context of renal cancer. Aim 1 will determine role of LC3C
structural elements in the autophagic degradation of SLC25A11/13 and in functional consequences for MAS
activity. We hypothesize that LC3C C-terminal peptide and P133 are necessary and potentially sufficient for this
activity. Aim 2 will identify metabolic effects of LC3C tumor suppressing activity. We hypothesize that LC3C will
(i) inhibit NAD/NADH regeneration and glycolytic activity and (ii) suppress export of aspartate from mitochondria
and its availability for biosynthetic pathways. Aim 3 will determine molecular mechanism by which glucose
regulates LC3C activity. We propose that LC3C autophagy is activated by sensing mitochondrial 2OG levels
through EGLN3-dependent hydroxylation of P133 in the C-terminal peptide. 2OG utilized by EGLN3-LC3C is
derived from glucose and exits mitochondria through SLC25A11, indicating that glucose oxidation is critical for
LC3C autophagic activity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Metabolic effects of cooper in renal cancer
-
批准号:10792732
-
项目类别:
-
资助金额:$57.85万
-
财政年份:2023
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Mechanisms of selective autophagy
-
批准号:10017261
-
项目类别:
-
资助金额:$32.1万
-
财政年份:2019
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Mechanisms of selective autophagy
-
批准号:9765722
-
项目类别:
-
资助金额:$31.47万
-
财政年份:2019
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Mechanisms of selective autophagy
-
批准号:10240490
-
项目类别:
-
资助金额:$32.1万
-
财政年份:2019
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Tumor suppressing pathways in renal cancer
-
批准号:10426280
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Tumor Suppressing Pathways in Renal Cancer
-
批准号:8398967
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Tumor Suppressing Pathways in Renal Cancer
-
批准号:8696822
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Tumor Suppressing Pathways in Kidney Cancer
-
批准号:10166749
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Tumor Suppressing Pathways in Renal Cancer
-
批准号:8305417
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Tumor Suppressing Pathways in Renal Cancer
-
批准号:8140551
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Tumor Suppressing Pathways in Kidney Cancer
-
批准号:9326809
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Molecular Mechanisms of Renal Cancer
-
批准号:8448354
-
项目类别:
-
资助金额:$29.14万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Role of ubiquitylation in renal cancer
-
批准号:8516794
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Role of ubiquitylation in renal cancer
-
批准号:7666796
-
项目类别:
-
资助金额:$29.64万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Role of ubiquitylation in renal cancer
-
批准号:7894585
-
项目类别:
-
资助金额:$29.64万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Molecular Mechanisms of Renal Cancer
-
批准号:8611902
-
项目类别:
-
资助金额:$28.34万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Role of ubiquitylation in renal cancer
-
批准号:7491622
-
项目类别:
-
资助金额:$29.64万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Molecular Mechanisms of Renal Cancer
-
批准号:8827261
-
项目类别:
-
资助金额:$29.14万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Role of ubiquitylation in renal cancer
-
批准号:7262804
-
项目类别:
-
资助金额:$29.64万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Role of ubiquitylation in renal cancer
-
批准号:8106369
-
项目类别:
-
资助金额:$28.75万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
海外基金